A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2018
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Genmab A/S
- 28 Nov 2018 This trial has been discontinued in Denmark.
- 14 Jun 2017 New trial record